IN2015DN02377A - - Google Patents

Info

Publication number
IN2015DN02377A
IN2015DN02377A IN2377DEN2015A IN2015DN02377A IN 2015DN02377 A IN2015DN02377 A IN 2015DN02377A IN 2377DEN2015 A IN2377DEN2015 A IN 2377DEN2015A IN 2015DN02377 A IN2015DN02377 A IN 2015DN02377A
Authority
IN
India
Prior art keywords
luliconazole
derivative
pharmaceutical composition
composition containing
amide
Prior art date
Application number
Other languages
English (en)
Inventor
Takaaki; Masuda
Hirokazu; Kobayashi
Original Assignee
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Pharma Inc, Nihon Nohyaku Co Ltd filed Critical Pola Pharma Inc
Publication of IN2015DN02377A publication Critical patent/IN2015DN02377A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2377DEN2015 2012-09-14 2013-08-28 IN2015DN02377A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012203293 2012-09-14
PCT/JP2013/073731 WO2014042043A1 (en) 2012-09-14 2013-08-28 Pharmaceutical composition containing luliconazole

Publications (1)

Publication Number Publication Date
IN2015DN02377A true IN2015DN02377A (enrdf_load_stackoverflow) 2015-09-04

Family

ID=49226452

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2377DEN2015 IN2015DN02377A (enrdf_load_stackoverflow) 2012-09-14 2013-08-28

Country Status (7)

Country Link
US (1) US20150238606A1 (enrdf_load_stackoverflow)
EP (1) EP2895164A1 (enrdf_load_stackoverflow)
JP (2) JP5686874B2 (enrdf_load_stackoverflow)
CN (1) CN104619320A (enrdf_load_stackoverflow)
IN (1) IN2015DN02377A (enrdf_load_stackoverflow)
RU (1) RU2621615C2 (enrdf_load_stackoverflow)
WO (1) WO2014042043A1 (enrdf_load_stackoverflow)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117089A2 (en) 2009-04-09 2010-10-14 Pola Pharma Inc. Antimycotic pharmaceutical composition
EP2416758B8 (en) 2009-04-09 2017-10-18 Pola Pharma Inc. Antimycotic pharmaceutical composition
EP2470178B1 (en) 2009-08-25 2018-10-17 Pola Pharma Inc. Antimycotic pharmaceutical composition
KR101806304B1 (ko) 2010-06-11 2017-12-07 가부시키가이샤 폴라 파마 항진균성 약학적 조성물
JP6265624B2 (ja) * 2012-05-11 2018-01-24 ロート製薬株式会社 ルリコナゾール含有外用医薬組成物
JP5460797B1 (ja) * 2012-09-14 2014-04-02 株式会社ポーラファルマ アミド誘導体及び安定性指標としてのその使用
EP2895165B1 (en) 2012-09-14 2016-12-14 Pola Pharma Inc. Crystal and pharmaceutical preparation containing the same crystal
WO2014041708A1 (en) 2012-09-14 2014-03-20 Pola Pharma Inc. Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
WO2014041846A1 (en) 2012-09-14 2014-03-20 Pola Pharma Inc. Use of surface free energy for differential evaluation of crystal, crystal evaluated on basis of surface free energy as index, and phrmaceutical composition prepared by containing the crystal
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP6503627B2 (ja) * 2013-03-28 2019-04-24 大正製薬株式会社 医薬液体組成物
JP5680161B1 (ja) 2013-09-06 2015-03-04 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP6242655B2 (ja) * 2013-10-29 2017-12-06 リンテック株式会社 機能性物質の放出方法、機能性物質の放出用キット及び放出性組成物
JP5587488B1 (ja) 2013-12-12 2014-09-10 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
MX2018014485A (es) * 2016-05-25 2019-08-12 Glenmark Pharmaceuticals Ltd Composiciones topicas estables de luliconazol.
CN107865825B (zh) * 2016-09-28 2022-05-20 四川海思科制药有限公司 一种卢立康唑外用喷雾剂药物组合物及其制备方法
WO2018179170A1 (ja) * 2017-03-29 2018-10-04 日本農薬株式会社 感染症を治療するための医薬組成物
MX2020004491A (es) * 2017-10-30 2020-08-13 Kaken Pharma Co Ltd Preparacion externa para tratar tinea unguium.
CN108143711A (zh) * 2018-01-13 2018-06-12 天津双硕医药科技有限公司 一种含有卢立康唑的外用乳膏组合物
US10898470B1 (en) * 2019-08-13 2021-01-26 Sato Pharmaceutical Co., Ltd. Pharmaceutical composition containing antifungal agent as active ingredient
CN113774390B (zh) * 2021-08-12 2023-08-04 上海新阳半导体材料股份有限公司 一种用于化学机械抛光后的清洗液及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007102242A1 (ja) * 2006-03-08 2007-09-13 Nihon Nohyaku Co., Ltd. 外用の医薬組成物
EP2025337B1 (en) 2006-03-08 2014-09-10 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
EP2005959B1 (en) 2006-03-08 2015-01-21 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
US8492421B2 (en) * 2007-08-27 2013-07-23 Nihon Nohyaku Co., Ltd. Agent for fungal dermatitis
EP2191827B1 (en) * 2007-09-05 2013-10-30 Pola Pharma Inc. Antifungal composition
US20100204293A1 (en) * 2007-09-05 2010-08-12 Pola Pharma Inc. Pharmaceutical composition
EP2191828B1 (en) 2007-09-05 2016-08-10 Pola Pharma Inc. Antifungal pharmaceutical composition
US20090130232A1 (en) * 2007-11-20 2009-05-21 Mohammed Zahra Composition and method for treatment of oral inflammation an ulceration
US8445717B2 (en) * 2008-11-20 2013-05-21 Chd Bioscience, Inc. α-Keto alkylperacids and methods for producing and using the same
EP2395839B1 (en) * 2009-02-13 2014-05-07 Topica Pharmaceuticals, Inc Anti-fungal formulation
EP2416758B8 (en) * 2009-04-09 2017-10-18 Pola Pharma Inc. Antimycotic pharmaceutical composition
WO2010117089A2 (en) * 2009-04-09 2010-10-14 Pola Pharma Inc. Antimycotic pharmaceutical composition
EP2470178B1 (en) * 2009-08-25 2018-10-17 Pola Pharma Inc. Antimycotic pharmaceutical composition
KR101806304B1 (ko) * 2010-06-11 2017-12-07 가부시키가이샤 폴라 파마 항진균성 약학적 조성물
US20120213835A1 (en) * 2011-02-17 2012-08-23 Chd Bioscience, Inc. Compositions Comprising Peroxy alpha-Ketocarboxylic Acid and Methods For Producing and Using the Same

Also Published As

Publication number Publication date
JP5686874B2 (ja) 2015-03-18
CN104619320A (zh) 2015-05-13
US20150238606A1 (en) 2015-08-27
EP2895164A1 (en) 2015-07-22
JP2014111672A (ja) 2014-06-19
JP2014074012A (ja) 2014-04-24
RU2621615C2 (ru) 2017-06-06
WO2014042043A9 (en) 2015-05-21
JP6215102B2 (ja) 2017-10-18
RU2015108930A (ru) 2016-11-10
WO2014042043A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
IN2015DN02377A (enrdf_load_stackoverflow)
MX2019009176A (es) Formulaciones de etanercept estabilizadas con iones metalicos.
BR112014017749A8 (pt) Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo
IN2012DE00888A (enrdf_load_stackoverflow)
MY160249A (en) Fatty acid fumarate derivatives and their uses
UA107865C2 (ru) Гетероциклические карбоксамиды
MX355428B (es) Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa.
EP4306171A3 (en) Formulation comprising a mek inhibitor
PH12015502154A1 (en) Composition for oral cavity
SG10201805198TA (en) 18f - fluciclovine compositions in citrate buffers
PH12015500334A1 (en) Azaindole carboxylic acid amides and azaindole thiocarboxylic acid amides for use as insecticides and acaricides
WO2014053401A3 (en) Method of improving plant health
BR112014002940A2 (pt) uso e composição agroquímica de dibutilamidas de ácido carboxílico
MY168438A (en) Handy calco-magnesian suspension
MX348979B (es) Agente de control de enfermedades de las plantas.
MX2015006223A (es) Composiciones farmaceuticas de inhibidores cetp.
MX2018006272A (es) Composicion para limitar formacion y/o aglomeracion de hidratos de gas.
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
MX2013004878A (es) N-hetarilmetil pirazolilcarboxamidas.
IN2014DN06122A (enrdf_load_stackoverflow)
UA114082C2 (xx) Спосіб одержання водорозчинних селеноглікопротеїнів та композиція, що їх містить
MX2010000693A (es) Composicion farmaceutica que comprende un compuesto de 11-desoxi-prostaglandina y metodo para establilizar el compuesto.
WO2014166836A8 (en) Growth hormone compound formulation
PH12017500763A1 (en) Nutritional compositions containing a prebiotic and lactoferrin and uses thereof
UA110822C2 (uk) Піперидинілмонокарбонові кислоти як агоністи s1p1-рецепторів